Recurrence rates in patients with HER2+ breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant trastuzumab: a real-world evidence study

Joyce O’Shaughnessy, Nicholas J. Robert, Srinivas Annavarapu, Jie Zhou, Jesse Sussell, Anna Cheng, Anita Fung